AU2013212264B2 - Sandalwood oil and its uses related to clostridium infections - Google Patents

Sandalwood oil and its uses related to clostridium infections Download PDF

Info

Publication number
AU2013212264B2
AU2013212264B2 AU2013212264A AU2013212264A AU2013212264B2 AU 2013212264 B2 AU2013212264 B2 AU 2013212264B2 AU 2013212264 A AU2013212264 A AU 2013212264A AU 2013212264 A AU2013212264 A AU 2013212264A AU 2013212264 B2 AU2013212264 B2 AU 2013212264B2
Authority
AU
Australia
Prior art keywords
subject
clostridium difficile
sandalwood oil
oil
sandalwood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013212264A
Other languages
English (en)
Other versions
AU2013212264A1 (en
Inventor
Paul Castella
Ian Clements
Corey Levenson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANTALIS PHARMACEUTICALS Inc
Original Assignee
SANTALIS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANTALIS PHARMACEUTICALS Inc filed Critical SANTALIS PHARMACEUTICALS Inc
Publication of AU2013212264A1 publication Critical patent/AU2013212264A1/en
Application granted granted Critical
Publication of AU2013212264B2 publication Critical patent/AU2013212264B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013212264A 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections Ceased AU2013212264B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589601P 2012-01-23 2012-01-23
US61/589,601 2012-01-23
PCT/US2013/022743 WO2013112582A1 (en) 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections

Publications (2)

Publication Number Publication Date
AU2013212264A1 AU2013212264A1 (en) 2014-08-07
AU2013212264B2 true AU2013212264B2 (en) 2017-05-18

Family

ID=48873861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013212264A Ceased AU2013212264B2 (en) 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections

Country Status (6)

Country Link
US (2) US9579354B2 (https=)
EP (1) EP2806882B1 (https=)
JP (1) JP6134739B2 (https=)
AU (1) AU2013212264B2 (https=)
CA (1) CA2862483A1 (https=)
WO (1) WO2013112582A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154342A1 (en) * 2011-07-28 2014-06-05 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to skin disorders
US9861670B2 (en) 2013-03-13 2018-01-09 Santalis Healthcare Corporation Stabilized cream formulations comprising sandalwood oil
JP2018529752A (ja) 2015-10-07 2018-10-11 サンタリス ファーマシューティカルズ インコーポレイテッド サンダルウッド油及び口腔粘膜炎に関連するその用途
BR112019018861A2 (pt) 2017-03-08 2023-10-10 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa
IL268883B (en) 2017-03-08 2022-09-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
EP3836947A4 (en) * 2018-08-17 2022-04-20 Universidad Andres Bello METHOD AND PHARMACOLOGICAL COMPOSITION FOR THE PREVENTION OF RECURRING INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE
CN111544353A (zh) * 2020-05-21 2020-08-18 天津芸熙生物技术有限公司 一种抑菌口腔喷雾剂及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058413A1 (en) * 2006-08-31 2008-03-06 Singh Chandra U Derivatives of sandalwood oil and santalols for treating cold sores and herpes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
JP2006124296A (ja) 2004-10-27 2006-05-18 Tomihiko Higuchi ヘリコバクター・ピロリ菌感染症治療のための医薬組成物
WO2009014781A2 (en) 2007-05-02 2009-01-29 Nucryst Pharmaceuticals Corp. Metal-containing materials for treatment of bacterial conditions
WO2011109411A2 (en) 2010-03-01 2011-09-09 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
MX2012013372A (es) 2010-05-18 2013-05-01 Optimer Pharmaceuticals Inc Metodos para tratar infecciones bacterianas recurrentes.
EP2613802A4 (en) * 2010-09-10 2014-03-26 Viropharma Inc ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058413A1 (en) * 2006-08-31 2008-03-06 Singh Chandra U Derivatives of sandalwood oil and santalols for treating cold sores and herpes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BURDOCK, G.A., et al., Food and Chemical Toxicology, 2008, vol. 46, pages 421–432 *
COHEN, S.H., et al., Infection Control and Hospital Epidemiology, 2010, vol. 31, pages 431-455 *
HUSSAIN, T., et al., Pak. J. Bot., 2011, vol. 43(1), pages 531-538 *
JIROVETZ, L. et al., Flavour and Fragrance Journal, 2006, vol. 21, pages 465–468 *
OCHI, T., et al., Journal of Natural Products, vol. 68, pages 819-824 *
WARNKE, P.H., et al., Journal of Cranio-Maxillofacial Surgery, 2009, vol. 37, pages 392-397 *

Also Published As

Publication number Publication date
JP6134739B2 (ja) 2017-05-24
EP2806882B1 (en) 2018-11-14
EP2806882A4 (en) 2015-08-05
WO2013112582A1 (en) 2013-08-01
US20170128509A1 (en) 2017-05-11
US10322154B2 (en) 2019-06-18
AU2013212264A1 (en) 2014-08-07
US20150238551A1 (en) 2015-08-27
EP2806882A1 (en) 2014-12-03
JP2015505540A (ja) 2015-02-23
CA2862483A1 (en) 2013-08-01
US9579354B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
US10322154B2 (en) Sandalwood oil and its uses related to clostridium infections
Bolder et al. The effect of flavophospholipol (Flavomycin) and salinomycin sodium (Sacox) on the excretion of Clostridium perfringens, Salmonella enteritidis, and Campylobacter jejuni in broilers after experimental infection
AU2019229354B2 (en) Volatile organic compound formulations having antimicrobial activity
KR20210004221A (ko) 알파-망고스틴, 감마-망고스틴 또는 셀라스트롤을 포함하는 항균활성을 가진 조성물
US11285122B2 (en) Volatile organic compound formulations having antimicrobial activity
Moore et al. The effect of an experimental chlorate product on Salmonella recovery of turkeys when administered prior to feed and water withdrawal
CN113423414A (zh) 具有抗微生物活性的挥发性有机化合物制剂
KR102208837B1 (ko) 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물
Mohammed et al. Lactobacillus salivarius bacteriocin and supernatant activity against Entamoeba histolytica in vitro and in vivo
US20220218637A1 (en) Volatile Organic Compound Formulations Having Antimicrobial Activity
HK40025284A (en) Volatile organic compound formulations having antimicrobial activity
JP2023172408A (ja) バンコマイシン耐性腸球菌の感染症を予防又は治療するための医薬及び腸内細菌叢のα－多様性向上剤
RU2802308C2 (ru) Композиции летучих органических веществ, обладающие антимикробной активностью
Kantas et al. A feed additive containing Bacillus toyonensis in weaning piglets
NZ715859B2 (en) Volatile organic compound formulations having antimicrobial activity
NZ754916B2 (en) Volatile organic compound formulations having antimicrobial activity
JP2010126472A (ja) クロストリジウム症の予防及び／又は治療用飼料

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired